Health-Related Quality-of-Life Instruments for Psoriasis

Psychocutaneous Medicine

Volumn , Issue , 2003, Pages 305-320

  Lin, Paula S ^a   Koo, John Y M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 51149119765     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203911877-23     Document Type: Chapter

References (21)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Psychodermatology 1996; 14:485-496.
2. Finlay AY, Kelly SE. Psoriasis—an index of disability. Clin Exp Dermatol 1987; 12:8-11.
3. Ginsburg I, Link B. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. J Invest Dermatol 1993; 32:587-591.
4. Ramsay B, O’Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988; 118:195-201.
5. Ashcroft D. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998; 23:391-398.
6. Gupta M, Gupta A. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 1995; 75:240-243.
7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-216.
8. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales—a measure of the impact of skin diseases. Br J Dermatol 1997; 136:202-206.
9. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997; 136:305-314.
10. Dawson-Saunders B, Trapp R. Summarizing Data. Basic and Clinical Biostatistics. Norwalk, CT: Appleton and Lange, 1994:41-63.
11. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. Soc Invest Dermatol 1996; 107:707-713.
12. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123:751-756.
13. Root S, Kent G, Al-Abadie MSK. The relationship between disease severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis. Dermatology 1994; 189:234-237.
14. O’Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. Br Med J 1996; 313:919-921.
15. Ware J, Sherbourne C. The MOS 36-Item Short-Form Health Survey (SF-36). Med Care 1992; 30:473-481.
16. Fortune DG, Main CJ, O’Sullivan TM, Griffiths CEM. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasisspecific stress. Br J Dermatol 1997; 137:755-760.
17. Kurwa H, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol 1995; 133:575-578.
18. Chren MM, Lasek RJ, Quinn LM, Covinsky KE. Convergent and discriminant validity of a generic and disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol 1997; 108:103-107.
19. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133:1433-1440.
20. Gupta M, Gupta A. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 1995; 34:700-703.
21. Dooley G, Finlay AY. Personal construct systems of psoriatic patients. Clin Exp Dermatol 1990; 15:401-405.